Oncology Pharma Inc
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated … Read more
Oncology Pharma Inc (ONPH) - Total Liabilities
Latest total liabilities as of December 2022: $1.04 Million USD
Based on the latest financial reports, Oncology Pharma Inc (ONPH) has total liabilities worth $1.04 Million USD as of December 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oncology Pharma Inc - Total Liabilities Trend (1996–2022)
This chart illustrates how Oncology Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oncology Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Oncology Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jupiter Marine International Holdings Inc
PINK:JMIH
|
USA | $3.31 Million |
|
APT Moto Vox Group Inc
PINK:MTVX
|
USA | $33.65 Million |
|
Sphere Resources Inc
PINK:SPHUF
|
USA | $3.55 Million |
|
Candlewood Hotel Company Inc
PINK:CNDL
|
USA | $232.11 Million |
|
V Group Inc
PINK:VGID
|
USA | $19.50K |
|
Davi Luxury Brand Group Inc
PINK:MDAV
|
USA | $328.30K |
|
MPM Technologies Inc
PINK:MPML
|
USA | $15.32 Million |
|
GuestLogix Inc
PINK:GUESF
|
USA | $45.83 Million |
Liability Composition Analysis (1996–2022)
This chart breaks down Oncology Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncology Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncology Pharma Inc (1996–2022)
The table below shows the annual total liabilities of Oncology Pharma Inc from 1996 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-03-31 | $875.47K | +69.15% |
| 2021-03-31 | $517.57K | +75.73% |
| 2020-03-31 | $294.52K | -26.95% |
| 2019-03-31 | $403.16K | -3.75% |
| 2013-03-31 | $418.86K | -37.15% |
| 2011-03-31 | $666.43K | +202.93% |
| 2004-03-31 | $220.00K | -74.97% |
| 2003-03-31 | $879.00K | -29.06% |
| 2002-03-31 | $1.24 Million | -14.63% |
| 2001-03-31 | $1.45 Million | -13.47% |
| 2000-03-31 | $1.68 Million | +65.26% |
| 1998-03-31 | $1.01 Million | -26.97% |
| 1997-03-31 | $1.39 Million | +4.85% |
| 1996-03-31 | $1.33 Million | -- |